HEADER TRANSCRIPTION ACTIVATOR 13-FEB-06 2G0H TITLE STRUCTURE-BASED DRUG DESIGN OF A NOVEL FAMILY OF PPAR TITLE 2 PARTIAL AGONISTS: VIRTUAL SCREENING, X-RAY CRYSTALLOGRAPHY TITLE 3 AND IN VITRO/IN VIVO BIOLOGICAL ACTIVITIES COMPND MOL_ID: 1; COMPND 2 MOLECULE: PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR GAMMA; COMPND 3 CHAIN: A, B; COMPND 4 FRAGMENT: LIGAND BINDING DOMAIN(RESIDUES 207-477); COMPND 5 SYNONYM: PPAR-GAMMA; COMPND 6 ENGINEERED: YES SOURCE MOL_ID: 1; SOURCE 2 ORGANISM_SCIENTIFIC: HOMO SAPIENS; SOURCE 3 ORGANISM_COMMON: HUMAN; SOURCE 4 ORGANISM_TAXID: 9606; SOURCE 5 GENE: PPARG, NR1C3; SOURCE 6 EXPRESSION_SYSTEM: ESCHERICHIA COLI BL21(DE3); SOURCE 7 EXPRESSION_SYSTEM_TAXID: 469008; SOURCE 8 EXPRESSION_SYSTEM_STRAIN: BL21(DE3); SOURCE 9 EXPRESSION_SYSTEM_VECTOR_TYPE: PLASMID; SOURCE 10 EXPRESSION_SYSTEM_PLASMID: PGEX6P-1 KEYWDS PPAR, TRANSCRIPTION ACTIVATOR EXPDTA X-RAY DIFFRACTION AUTHOR I.L.LU,Y.H.PENG,C.F.HUANG,Y.T.LIN,J.T.A.HSU,S.Y.WU REVDAT 2 24-FEB-09 2G0H 1 VERSN REVDAT 1 16-MAY-06 2G0H 0 JRNL AUTH I.L.LU,C.F.HUANG,Y.H.PENG,Y.T.LIN,H.P.HSIEH, JRNL AUTH 2 C.T.CHEN,T.W.LIEN,H.J.LEE,N.MAHINDROO,E.PRAKASH, JRNL AUTH 3 A.YUEH,H.Y.CHEN,C.M.GOPARAJU,X.CHEN,C.C.LIAO, JRNL AUTH 4 Y.S.CHAO,J.T.HSU,S.Y.WU JRNL TITL STRUCTURE-BASED DRUG DESIGN OF A NOVEL FAMILY OF JRNL TITL 2 PPARGAMMA PARTIAL AGONISTS: VIRTUAL SCREENING, JRNL TITL 3 X-RAY CRYSTALLOGRAPHY, AND IN VITRO/IN VIVO JRNL TITL 4 BIOLOGICAL ACTIVITIES JRNL REF J.MED.CHEM. V. 49 2703 2006 JRNL REFN ISSN 0022-2623 JRNL PMID 16640330 JRNL DOI 10.1021/JM051129S REMARK 1 REMARK 2 REMARK 2 RESOLUTION. 2.30 ANGSTROMS. REMARK 3 REMARK 3 REFINEMENT. REMARK 3 PROGRAM : REFMAC 5 REMARK 3 AUTHORS : MURSHUDOV,VAGIN,DODSON REMARK 3 REMARK 3 REFINEMENT TARGET : ENGH & HUBER REMARK 3 REMARK 3 DATA USED IN REFINEMENT. REMARK 3 RESOLUTION RANGE HIGH (ANGSTROMS) : 2.30 REMARK 3 RESOLUTION RANGE LOW (ANGSTROMS) : 20.00 REMARK 3 DATA CUTOFF (SIGMA(F)) : 3.780 REMARK 3 COMPLETENESS FOR RANGE (%) : NULL REMARK 3 NUMBER OF REFLECTIONS : 24250 REMARK 3 REMARK 3 FIT TO DATA USED IN REFINEMENT. REMARK 3 CROSS-VALIDATION METHOD : NULL REMARK 3 FREE R VALUE TEST SET SELECTION : RANDOM REMARK 3 R VALUE (WORKING + TEST SET) : 0.238 REMARK 3 R VALUE (WORKING SET) : 0.238 REMARK 3 FREE R VALUE : 0.293 REMARK 3 FREE R VALUE TEST SET SIZE (%) : NULL REMARK 3 FREE R VALUE TEST SET COUNT : 1320 REMARK 3 REMARK 3 FIT IN THE HIGHEST RESOLUTION BIN. REMARK 3 TOTAL NUMBER OF BINS USED : NULL REMARK 3 BIN RESOLUTION RANGE HIGH (A) : NULL REMARK 3 BIN RESOLUTION RANGE LOW (A) : NULL REMARK 3 REFLECTION IN BIN (WORKING SET) : NULL REMARK 3 BIN COMPLETENESS (WORKING+TEST) (%) : NULL REMARK 3 BIN R VALUE (WORKING SET) : NULL REMARK 3 BIN FREE R VALUE SET COUNT : NULL REMARK 3 BIN FREE R VALUE : NULL REMARK 3 REMARK 3 NUMBER OF NON-HYDROGEN ATOMS USED IN REFINEMENT. REMARK 3 PROTEIN ATOMS : 4354 REMARK 3 NUCLEIC ACID ATOMS : 0 REMARK 3 HETEROGEN ATOMS : 70 REMARK 3 SOLVENT ATOMS : 87 REMARK 3 REMARK 3 B VALUES. REMARK 3 FROM WILSON PLOT (A**2) : NULL REMARK 3 MEAN B VALUE (OVERALL, A**2) : NULL REMARK 3 OVERALL ANISOTROPIC B VALUE. REMARK 3 B11 (A**2) : NULL REMARK 3 B22 (A**2) : NULL REMARK 3 B33 (A**2) : NULL REMARK 3 B12 (A**2) : NULL REMARK 3 B13 (A**2) : NULL REMARK 3 B23 (A**2) : NULL REMARK 3 REMARK 3 ESTIMATED OVERALL COORDINATE ERROR. REMARK 3 ESU BASED ON R VALUE (A): NULL REMARK 3 ESU BASED ON FREE R VALUE (A): NULL REMARK 3 ESU BASED ON MAXIMUM LIKELIHOOD (A): NULL REMARK 3 ESU FOR B VALUES BASED ON MAXIMUM LIKELIHOOD (A**2): NULL REMARK 3 REMARK 3 CORRELATION COEFFICIENTS. REMARK 3 CORRELATION COEFFICIENT FO-FC : NULL REMARK 3 CORRELATION COEFFICIENT FO-FC FREE : NULL REMARK 3 REMARK 3 RMS DEVIATIONS FROM IDEAL VALUES COUNT RMS WEIGHT REMARK 3 BOND LENGTHS REFINED ATOMS (A): NULL ; 0.008 ; NULL REMARK 3 BOND LENGTHS OTHERS (A): NULL ; NULL ; NULL REMARK 3 BOND ANGLES REFINED ATOMS (DEGREES): NULL ; 1.796 ; NULL REMARK 3 BOND ANGLES OTHERS (DEGREES): NULL ; NULL ; NULL REMARK 3 TORSION ANGLES, PERIOD 1 (DEGREES): NULL ; NULL ; NULL REMARK 3 TORSION ANGLES, PERIOD 2 (DEGREES): NULL ; NULL ; NULL REMARK 3 TORSION ANGLES, PERIOD 3 (DEGREES): NULL ; NULL ; NULL REMARK 3 TORSION ANGLES, PERIOD 4 (DEGREES): NULL ; NULL ; NULL REMARK 3 CHIRAL-CENTER RESTRAINTS (A**3): NULL ; NULL ; NULL REMARK 3 GENERAL PLANES REFINED ATOMS (A): NULL ; NULL ; NULL REMARK 3 GENERAL PLANES OTHERS (A): NULL ; NULL ; NULL REMARK 3 NON-BONDED CONTACTS REFINED ATOMS (A): NULL ; NULL ; NULL REMARK 3 NON-BONDED CONTACTS OTHERS (A): NULL ; NULL ; NULL REMARK 3 NON-BONDED TORSION REFINED ATOMS (A): NULL ; NULL ; NULL REMARK 3 NON-BONDED TORSION OTHERS (A): NULL ; NULL ; NULL REMARK 3 H-BOND (X...Y) REFINED ATOMS (A): NULL ; NULL ; NULL REMARK 3 H-BOND (X...Y) OTHERS (A): NULL ; NULL ; NULL REMARK 3 POTENTIAL METAL-ION REFINED ATOMS (A): NULL ; NULL ; NULL REMARK 3 POTENTIAL METAL-ION OTHERS (A): NULL ; NULL ; NULL REMARK 3 SYMMETRY VDW REFINED ATOMS (A): NULL ; NULL ; NULL REMARK 3 SYMMETRY VDW OTHERS (A): NULL ; NULL ; NULL REMARK 3 SYMMETRY H-BOND REFINED ATOMS (A): NULL ; NULL ; NULL REMARK 3 SYMMETRY H-BOND OTHERS (A): NULL ; NULL ; NULL REMARK 3 SYMMETRY METAL-ION REFINED ATOMS (A): NULL ; NULL ; NULL REMARK 3 SYMMETRY METAL-ION OTHERS (A): NULL ; NULL ; NULL REMARK 3 REMARK 3 ISOTROPIC THERMAL FACTOR RESTRAINTS. COUNT RMS WEIGHT REMARK 3 MAIN-CHAIN BOND REFINED ATOMS (A**2): NULL ; NULL ; NULL REMARK 3 MAIN-CHAIN BOND OTHER ATOMS (A**2): NULL ; NULL ; NULL REMARK 3 MAIN-CHAIN ANGLE REFINED ATOMS (A**2): NULL ; NULL ; NULL REMARK 3 SIDE-CHAIN BOND REFINED ATOMS (A**2): NULL ; NULL ; NULL REMARK 3 SIDE-CHAIN ANGLE REFINED ATOMS (A**2): NULL ; NULL ; NULL REMARK 3 REMARK 3 ANISOTROPIC THERMAL FACTOR RESTRAINTS. COUNT RMS WEIGHT REMARK 3 RIGID-BOND RESTRAINTS (A**2): NULL ; NULL ; NULL REMARK 3 SPHERICITY; FREE ATOMS (A**2): NULL ; NULL ; NULL REMARK 3 SPHERICITY; BONDED ATOMS (A**2): NULL ; NULL ; NULL REMARK 3 REMARK 3 NCS RESTRAINTS STATISTICS REMARK 3 NUMBER OF DIFFERENT NCS GROUPS : NULL REMARK 3 REMARK 3 TLS DETAILS REMARK 3 NUMBER OF TLS GROUPS : NULL REMARK 3 REMARK 3 BULK SOLVENT MODELLING. REMARK 3 METHOD USED : NULL REMARK 3 PARAMETERS FOR MASK CALCULATION REMARK 3 VDW PROBE RADIUS : NULL REMARK 3 ION PROBE RADIUS : NULL REMARK 3 SHRINKAGE RADIUS : NULL REMARK 3 REMARK 3 OTHER REFINEMENT REMARKS: NULL REMARK 4 REMARK 4 2G0H COMPLIES WITH FORMAT V. 3.15, 01-DEC-08 REMARK 100 REMARK 100 THIS ENTRY HAS BEEN PROCESSED BY PDBJ ON 16-FEB-06. REMARK 100 THE RCSB ID CODE IS RCSB036533. REMARK 200 REMARK 200 EXPERIMENTAL DETAILS REMARK 200 EXPERIMENT TYPE : X-RAY DIFFRACTION REMARK 200 DATE OF DATA COLLECTION : 26-MAY-05 REMARK 200 TEMPERATURE (KELVIN) : 100 REMARK 200 PH : 8.0 REMARK 200 NUMBER OF CRYSTALS USED : 1 REMARK 200 REMARK 200 SYNCHROTRON (Y/N) : Y REMARK 200 RADIATION SOURCE : SPRING-8 REMARK 200 BEAMLINE : BL12B2 REMARK 200 X-RAY GENERATOR MODEL : NULL REMARK 200 MONOCHROMATIC OR LAUE (M/L) : M REMARK 200 WAVELENGTH OR RANGE (A) : 1.0 REMARK 200 MONOCHROMATOR : MONOCHROMATOR REMARK 200 OPTICS : NULL REMARK 200 REMARK 200 DETECTOR TYPE : CCD REMARK 200 DETECTOR MANUFACTURER : ADSC QUANTUM 4 REMARK 200 INTENSITY-INTEGRATION SOFTWARE : HKL-2000 REMARK 200 DATA SCALING SOFTWARE : SCALEPACK REMARK 200 REMARK 200 NUMBER OF UNIQUE REFLECTIONS : 24250 REMARK 200 RESOLUTION RANGE HIGH (A) : 2.300 REMARK 200 RESOLUTION RANGE LOW (A) : 20.000 REMARK 200 REJECTION CRITERIA (SIGMA(I)) : 0.000 REMARK 200 REMARK 200 OVERALL. REMARK 200 COMPLETENESS FOR RANGE (%) : 99.8 REMARK 200 DATA REDUNDANCY : NULL REMARK 200 R MERGE (I) : NULL REMARK 200 R SYM (I) : NULL REMARK 200 FOR THE DATA SET : NULL REMARK 200 REMARK 200 IN THE HIGHEST RESOLUTION SHELL. REMARK 200 HIGHEST RESOLUTION SHELL, RANGE HIGH (A) : 2.30 REMARK 200 HIGHEST RESOLUTION SHELL, RANGE LOW (A) : 2.36 REMARK 200 COMPLETENESS FOR SHELL (%) : 100.0 REMARK 200 DATA REDUNDANCY IN SHELL : NULL REMARK 200 R MERGE FOR SHELL (I) : NULL REMARK 200 R SYM FOR SHELL (I) : NULL REMARK 200 FOR SHELL : NULL REMARK 200 REMARK 200 DIFFRACTION PROTOCOL: SINGLE WAVELENGTH REMARK 200 METHOD USED TO DETERMINE THE STRUCTURE: MOLECULAR REPLACEMENT REMARK 200 SOFTWARE USED: MOLREP REMARK 200 STARTING MODEL: 2ATH REMARK 200 REMARK 200 REMARK: NULL REMARK 280 REMARK 280 CRYSTAL REMARK 280 SOLVENT CONTENT, VS (%): 47.85 REMARK 280 MATTHEWS COEFFICIENT, VM (ANGSTROMS**3/DA): 2.36 REMARK 280 REMARK 280 CRYSTALLIZATION CONDITIONS: 20% PEG3350, PH 8.0, VAPOR REMARK 280 DIFFUSION, HANGING DROP, TEMPERATURE 291K REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY REMARK 290 SYMMETRY OPERATORS FOR SPACE GROUP: P 1 21 1 REMARK 290 REMARK 290 SYMOP SYMMETRY REMARK 290 NNNMMM OPERATOR REMARK 290 1555 X,Y,Z REMARK 290 2555 -X,Y+1/2,-Z REMARK 290 REMARK 290 WHERE NNN -> OPERATOR NUMBER REMARK 290 MMM -> TRANSLATION VECTOR REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY TRANSFORMATIONS REMARK 290 THE FOLLOWING TRANSFORMATIONS OPERATE ON THE ATOM/HETATM REMARK 290 RECORDS IN THIS ENTRY TO PRODUCE CRYSTALLOGRAPHICALLY REMARK 290 RELATED MOLECULES. REMARK 290 SMTRY1 1 1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 1 0.000000 1.000000 0.000000 0.00000 REMARK 290 SMTRY3 1 0.000000 0.000000 1.000000 0.00000 REMARK 290 SMTRY1 2 -1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 2 0.000000 1.000000 0.000000 44.44850 REMARK 290 SMTRY3 2 0.000000 0.000000 -1.000000 0.00000 REMARK 290 REMARK 290 REMARK: NULL REMARK 300 REMARK 300 BIOMOLECULE: 1 REMARK 300 SEE REMARK 350 FOR THE AUTHOR PROVIDED AND/OR PROGRAM REMARK 300 GENERATED ASSEMBLY INFORMATION FOR THE STRUCTURE IN REMARK 300 THIS ENTRY. THE REMARK MAY ALSO PROVIDE INFORMATION ON REMARK 300 BURIED SURFACE AREA. REMARK 300 REMARK: THE SECOND PART OF THE BIOLOGICAL ASSEMBLY IS GENERATED REMARK 300 BY THE TWO FOLD AXIS: REMARK 300 -X, Y+1/2, -Z; REMARK 350 REMARK 350 COORDINATES FOR A COMPLETE MULTIMER REPRESENTING THE KNOWN REMARK 350 BIOLOGICALLY SIGNIFICANT OLIGOMERIZATION STATE OF THE REMARK 350 MOLECULE CAN BE GENERATED BY APPLYING BIOMT TRANSFORMATIONS REMARK 350 GIVEN BELOW. BOTH NON-CRYSTALLOGRAPHIC AND REMARK 350 CRYSTALLOGRAPHIC OPERATIONS ARE GIVEN. REMARK 350 REMARK 350 BIOMOLECULE: 1 REMARK 350 AUTHOR DETERMINED BIOLOGICAL UNIT: DIMERIC REMARK 350 APPLY THE FOLLOWING TO CHAINS: A, B REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: COVALENT BOND ANGLES REMARK 500 REMARK 500 THE STEREOCHEMICAL PARAMETERS OF THE FOLLOWING RESIDUES REMARK 500 HAVE VALUES WHICH DEVIATE FROM EXPECTED VALUES BY MORE REMARK 500 THAN 6*RMSD (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN REMARK 500 IDENTIFIER; SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT: (10X,I3,1X,A3,1X,A1,I4,A1,3(1X,A4,2X),12X,F5.1) REMARK 500 REMARK 500 EXPECTED VALUES PROTEIN: ENGH AND HUBER, 1999 REMARK 500 EXPECTED VALUES NUCLEIC ACID: CLOWNEY ET AL 1996 REMARK 500 REMARK 500 M RES CSSEQI ATM1 ATM2 ATM3 REMARK 500 ASP A 243 N - CA - CB ANGL. DEV. = 13.3 DEGREES REMARK 500 REMARK 500 REMARK: NULL REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: TORSION ANGLES REMARK 500 REMARK 500 TORSION ANGLES OUTSIDE THE EXPECTED RAMACHANDRAN REGIONS: REMARK 500 (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN IDENTIFIER; REMARK 500 SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT:(10X,I3,1X,A3,1X,A1,I4,A1,4X,F7.2,3X,F7.2) REMARK 500 REMARK 500 EXPECTED VALUES: GJ KLEYWEGT AND TA JONES (1996). PHI/PSI- REMARK 500 CHOLOGY: RAMACHANDRAN REVISITED. STRUCTURE 4, 1395 - 1400 REMARK 500 REMARK 500 M RES CSSEQI PSI PHI REMARK 500 THR A 242 45.48 -99.64 REMARK 500 LYS A 244 -156.68 34.74 REMARK 500 SER A 245 115.09 171.06 REMARK 500 ILE A 262 92.78 -50.12 REMARK 500 LYS A 263 -38.40 -145.11 REMARK 500 HIS A 266 -167.16 -67.59 REMARK 500 PRO A 269 -17.12 -42.38 REMARK 500 GLN A 271 -160.48 -76.94 REMARK 500 GLN A 273 53.75 -67.59 REMARK 500 LYS A 275 -141.30 -160.03 REMARK 500 VAL A 277 -96.94 20.88 REMARK 500 PHE A 282 -37.03 -39.63 REMARK 500 ASP A 310 134.04 -39.81 REMARK 500 MET A 348 80.71 -166.80 REMARK 500 THR A 349 146.41 -35.23 REMARK 500 LYS A 358 -54.51 -21.97 REMARK 500 PHE A 360 0.49 -63.27 REMARK 500 LEU A 393 44.42 -80.91 REMARK 500 LEU A 453 -7.09 -49.00 REMARK 500 THR A 461 -164.50 -100.92 REMARK 500 ASP A 462 136.95 -38.64 REMARK 500 MET A 463 -85.61 -122.41 REMARK 500 SER A 464 141.53 69.60 REMARK 500 HIS A 466 131.61 -38.86 REMARK 500 ASP A 475 16.35 59.33 REMARK 500 THR B 238 -91.93 -92.83 REMARK 500 THR B 241 72.08 30.10 REMARK 500 THR B 242 105.50 -46.87 REMARK 500 ASP B 243 -42.30 -134.22 REMARK 500 LYS B 244 64.39 -166.10 REMARK 500 MET B 257 -18.54 -49.29 REMARK 500 ILE B 262 21.13 -144.85 REMARK 500 LYS B 263 -53.76 -158.15 REMARK 500 ILE B 267 82.33 -69.05 REMARK 500 GLU B 272 -175.23 -63.57 REMARK 500 SER B 274 173.22 60.93 REMARK 500 LYS B 275 153.93 78.21 REMARK 500 ASP B 310 132.65 -39.34 REMARK 500 ASN B 335 -165.11 -120.39 REMARK 500 HIS B 425 57.48 -142.04 REMARK 500 SER B 464 96.71 66.86 REMARK 500 LEU B 468 -72.10 -50.75 REMARK 500 LEU B 469 32.82 -90.42 REMARK 500 ASP B 475 70.59 53.49 REMARK 500 LEU B 476 -153.56 -108.01 REMARK 500 REMARK 500 REMARK: NULL REMARK 800 REMARK 800 SITE REMARK 800 SITE_IDENTIFIER: AC1 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE SP3 A 101 REMARK 800 SITE_IDENTIFIER: AC2 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE SP3 B 201 REMARK 900 REMARK 900 RELATED ENTRIES REMARK 900 RELATED ID: 2G0G RELATED DB: PDB REMARK 900 THE SAME PROTEIN COMPLEXED WITH DIFFERENT LIGAND DBREF 2G0H A 207 477 UNP Q86U60 PPARG_HUMAN 235 505 DBREF 2G0H B 207 477 UNP Q86U60 PPARG_HUMAN 235 505 SEQRES 1 A 271 GLU SER ALA ASP LEU ARG ALA LEU ALA LYS HIS LEU TYR SEQRES 2 A 271 ASP SER TYR ILE LYS SER PHE PRO LEU THR LYS ALA LYS SEQRES 3 A 271 ALA ARG ALA ILE LEU THR GLY LYS THR THR ASP LYS SER SEQRES 4 A 271 PRO PHE VAL ILE TYR ASP MET ASN SER LEU MET MET GLY SEQRES 5 A 271 GLU ASP LYS ILE LYS PHE LYS HIS ILE THR PRO LEU GLN SEQRES 6 A 271 GLU GLN SER LYS GLU VAL ALA ILE ARG ILE PHE GLN GLY SEQRES 7 A 271 CYS GLN PHE ARG SER VAL GLU ALA VAL GLN GLU ILE THR SEQRES 8 A 271 GLU TYR ALA LYS SER ILE PRO GLY PHE VAL ASN LEU ASP SEQRES 9 A 271 LEU ASN ASP GLN VAL THR LEU LEU LYS TYR GLY VAL HIS SEQRES 10 A 271 GLU ILE ILE TYR THR MET LEU ALA SER LEU MET ASN LYS SEQRES 11 A 271 ASP GLY VAL LEU ILE SER GLU GLY GLN GLY PHE MET THR SEQRES 12 A 271 ARG GLU PHE LEU LYS SER LEU ARG LYS PRO PHE GLY ASP SEQRES 13 A 271 PHE MET GLU PRO LYS PHE GLU PHE ALA VAL LYS PHE ASN SEQRES 14 A 271 ALA LEU GLU LEU ASP ASP SER ASP LEU ALA ILE PHE ILE SEQRES 15 A 271 ALA VAL ILE ILE LEU SER GLY ASP ARG PRO GLY LEU LEU SEQRES 16 A 271 ASN VAL LYS PRO ILE GLU ASP ILE GLN ASP ASN LEU LEU SEQRES 17 A 271 GLN ALA LEU GLU LEU GLN LEU LYS LEU ASN HIS PRO GLU SEQRES 18 A 271 SER SER GLN LEU PHE ALA LYS LEU LEU GLN LYS MET THR SEQRES 19 A 271 ASP LEU ARG GLN ILE VAL THR GLU HIS VAL GLN LEU LEU SEQRES 20 A 271 GLN VAL ILE LYS LYS THR GLU THR ASP MET SER LEU HIS SEQRES 21 A 271 PRO LEU LEU GLN GLU ILE TYR LYS ASP LEU TYR SEQRES 1 B 271 GLU SER ALA ASP LEU ARG ALA LEU ALA LYS HIS LEU TYR SEQRES 2 B 271 ASP SER TYR ILE LYS SER PHE PRO LEU THR LYS ALA LYS SEQRES 3 B 271 ALA ARG ALA ILE LEU THR GLY LYS THR THR ASP LYS SER SEQRES 4 B 271 PRO PHE VAL ILE TYR ASP MET ASN SER LEU MET MET GLY SEQRES 5 B 271 GLU ASP LYS ILE LYS PHE LYS HIS ILE THR PRO LEU GLN SEQRES 6 B 271 GLU GLN SER LYS GLU VAL ALA ILE ARG ILE PHE GLN GLY SEQRES 7 B 271 CYS GLN PHE ARG SER VAL GLU ALA VAL GLN GLU ILE THR SEQRES 8 B 271 GLU TYR ALA LYS SER ILE PRO GLY PHE VAL ASN LEU ASP SEQRES 9 B 271 LEU ASN ASP GLN VAL THR LEU LEU LYS TYR GLY VAL HIS SEQRES 10 B 271 GLU ILE ILE TYR THR MET LEU ALA SER LEU MET ASN LYS SEQRES 11 B 271 ASP GLY VAL LEU ILE SER GLU GLY GLN GLY PHE MET THR SEQRES 12 B 271 ARG GLU PHE LEU LYS SER LEU ARG LYS PRO PHE GLY ASP SEQRES 13 B 271 PHE MET GLU PRO LYS PHE GLU PHE ALA VAL LYS PHE ASN SEQRES 14 B 271 ALA LEU GLU LEU ASP ASP SER ASP LEU ALA ILE PHE ILE SEQRES 15 B 271 ALA VAL ILE ILE LEU SER GLY ASP ARG PRO GLY LEU LEU SEQRES 16 B 271 ASN VAL LYS PRO ILE GLU ASP ILE GLN ASP ASN LEU LEU SEQRES 17 B 271 GLN ALA LEU GLU LEU GLN LEU LYS LEU ASN HIS PRO GLU SEQRES 18 B 271 SER SER GLN LEU PHE ALA LYS LEU LEU GLN LYS MET THR SEQRES 19 B 271 ASP LEU ARG GLN ILE VAL THR GLU HIS VAL GLN LEU LEU SEQRES 20 B 271 GLN VAL ILE LYS LYS THR GLU THR ASP MET SER LEU HIS SEQRES 21 B 271 PRO LEU LEU GLN GLU ILE TYR LYS ASP LEU TYR HET SP3 A 101 35 HET SP3 B 201 35 HETNAM SP3 N-[1-(4-FLUOROPHENYL)-3-(2-THIENYL)-1H-PYRAZOL-5-YL]- HETNAM 2 SP3 3,5-BIS(TRIFLUOROMETHYL)BENZENESULFONAMIDE FORMUL 3 SP3 2(C21 H12 F7 N3 O2 S2) FORMUL 5 HOH *87(H2 O) HELIX 1 1 GLU A 207 PHE A 226 1 20 HELIX 2 2 THR A 229 GLY A 239 1 11 HELIX 3 3 ASP A 251 GLU A 259 1 9 HELIX 4 4 GLU A 276 SER A 302 1 27 HELIX 5 5 ASP A 310 SER A 332 1 23 HELIX 6 6 THR A 349 LYS A 354 1 6 HELIX 7 7 PRO A 359 PHE A 363 5 5 HELIX 8 8 MET A 364 ALA A 376 1 13 HELIX 9 9 ASP A 380 LEU A 393 1 14 HELIX 10 10 ASN A 402 HIS A 425 1 24 HELIX 11 11 GLN A 430 GLU A 460 1 31 HELIX 12 12 HIS A 466 TYR A 473 1 8 HELIX 13 13 GLU B 207 PHE B 226 1 20 HELIX 14 14 THR B 229 GLY B 239 1 11 HELIX 15 15 ASP B 251 MET B 257 1 7 HELIX 16 16 GLU B 276 SER B 302 1 27 HELIX 17 17 ASP B 310 ALA B 331 1 22 HELIX 18 18 SER B 342 GLY B 344 5 3 HELIX 19 19 ARG B 350 LEU B 356 1 7 HELIX 20 20 PRO B 359 PHE B 363 5 5 HELIX 21 21 MET B 364 ALA B 376 1 13 HELIX 22 22 ASP B 380 LEU B 393 1 14 HELIX 23 23 ASN B 402 HIS B 425 1 24 HELIX 24 24 GLN B 430 GLU B 460 1 31 SHEET 1 A 4 PHE B 247 ILE B 249 0 SHEET 2 A 4 GLY B 346 THR B 349 1 O PHE B 347 N ILE B 249 SHEET 3 A 4 GLY B 338 ILE B 341 -1 N VAL B 339 O MET B 348 SHEET 4 A 4 MET B 334 ASN B 335 -1 N ASN B 335 O GLY B 338 SITE 1 AC1 19 PHE A 282 CYS A 285 GLN A 286 ARG A 288 SITE 2 AC1 19 SER A 289 ILE A 326 TYR A 327 LEU A 330 SITE 3 AC1 19 VAL A 339 ILE A 341 PHE A 360 PHE A 363 SITE 4 AC1 19 MET A 364 LYS A 367 HIS A 449 LEU A 453 SITE 5 AC1 19 LEU A 465 LEU A 469 TYR A 473 SITE 1 AC2 15 ILE B 281 PHE B 282 CYS B 285 GLN B 286 SITE 2 AC2 15 ARG B 288 SER B 289 ILE B 326 TYR B 327 SITE 3 AC2 15 VAL B 339 ILE B 341 PHE B 363 MET B 364 SITE 4 AC2 15 LYS B 367 HIS B 449 LEU B 469 CRYST1 56.301 88.897 58.451 90.00 90.80 90.00 P 1 21 1 4 ORIGX1 1.000000 0.000000 0.000000 0.00000 ORIGX2 0.000000 1.000000 0.000000 0.00000 ORIGX3 0.000000 0.000000 1.000000 0.00000 SCALE1 0.017762 0.000000 0.000248 0.00000 SCALE2 0.000000 0.011249 0.000000 0.00000 SCALE3 0.000000 0.000000 0.017110 0.00000 MASTER 316 0 2 24 4 0 9 6 0 0 0 42 END